Search results
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial ...
Teva, a global leader in generics and specialty medicines, announced the completion of its acquisition of Allergan's generics business in August 2016. The acquisition strengthened Teva's financial profile, product pipeline, global reach and operational efficiency.
Actavis Indonesia offers innovative, accessible and high-quality medicines in various therapeutic areas. Learn more about their OTC, generic and specialty products, and their dedication to patient safety and quality.
Feb 18, 2014 · Actavis, a global specialty pharmaceutical company, announced in 2014 that it would buy Forest Laboratories, a North American specialty brand company, for $25 billion. The deal created a diversified and balanced portfolio of products, a strong pipeline and a leading position in CNS, GI, Women's Health and Urology.
Nov 23, 2014 · Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue. November 23, 2014. Article. - Transaction Valued at $66 Billion or $219 per Share in Cash and Actavis Shares -. - Fastest Growing, Most Dynamic Pharmaceutical Company in Global Healthcare -. - Leading Blockbuster Franchises in ...
Teva Pharmaceuticals explains how it combined with Actavis Generics to become the largest generic pharmaceutical company in the world. The deal involved a complex financing structure, a smooth integration and a focus on savings and efficiency.
People also ask
What is Actavis Generics?
Where is Actavis based?
Is Actavis a branded pharmaceutical company?
How did Actavis become a company?
Feb 18, 2014 · Actavis (ACT) agreed to buy Forest Laboratories for $25 billion in cash and stock in 2014, creating a new kind of specialty pharmaceutical company. The deal combined generic and branded drugs, including Forest's dementia drug Namenda and gastrointestinal franchise.
